Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Diageo plc stock: Kenya court delay keeps $2.3bn Asahi deal in focus ahead of next week

Diageo plc stock: Kenya court delay keeps $2.3bn Asahi deal in focus ahead of next week

Kenya’s High Court has pushed the hearing on a bid to block Diageo’s $2.3 billion sale of its local unit EABL to Japan’s Asahi Holdings to Jan. 20. Judge Bahati Mwamuye said the involved parties can proceed with preliminary moves, provided the deal isn’t finalized before that date. EABL responded, “We welcome the court's decision to allow the regulatory phases of this transaction to continue.” The lawsuit was brought by Kenyan beer distributor Bia Tosha, tied to a dispute going back to 2016. Despite the hold-up, the deal parties still aim to close in the second half of the year.
10 January 2026
···
GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

AnaptysBio said it filed a motion asking a U.S. court to dismiss part of a claim by GSK plc’s oncology unit, escalating a dispute over royalties tied to sales of cancer drug Jemperli, a PD-1 inhibitor — a kind of immunotherapy that helps the immune system attack tumours. Tesaro sued AnaptysBio in Delaware in November seeking to terminate a 2014 licence and halve royalty and milestone payments, while AnaptysBio countersued and pointed to trials involving rival PD-1 drugs including Merck’s Keytruda; the case is set for a July 14–17 trial and the court is expected to hear the motion by early March, with royalties under the licence rising to 25% on annual sales above $2.5 billion through patents expiring in 2035-36. GSK did not immediately respond to a request for comment, and its U.S.-listed shares ended Friday up 0.3% at $50.39.
10 January 2026
····
Shell stock: buyback questions linger after Q4 chemicals warning, shares bounce back

Shell stock: buyback questions linger after Q4 chemicals warning, shares bounce back

Shell said its Chemicals and Products segment is expected to be below break-even in the fourth quarter, as its indicative chemicals margin drops to $140 a tonne and trading and optimisation falls from the previous quarter. It expects an indicative refining margin of $14 a barrel, kept its production outlook within prior ranges — upstream at 1.84 million to 1.94 million boed and LNG, or liquefied natural gas, liquefaction at 7.5 million to 7.9 million tonnes — and plans to publish full results on Feb. 5.
10 January 2026
··
1 … 289 290 291 292 293 … 610
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Xylem

NYSE: XYL 95 / 100
#2 BUY

AerCap

NYSE: AER 93 / 100
#3 BUY ON WEAKNESS

Visa

NYSE: V 90 / 100
#4 TACTICAL BUY

Chevron

NYSE: CVX 87 / 100
#5 ACCUMULATE

UPS

NYSE: UPS 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.